Monocyte gene expression and coronary artery disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 16, Issue 4, 2013, Pages 411-417

  Maiwald, Stephanie ^a   Zwetsloot, Peter Paul ^b,c   Sivapalaratnam, Suthesh ^a,c   Dallinga Thie, Geesje M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Gene expression; Monocytes

Indexed keywords

ABC TRANSPORTER A1; ACETYLSALICYLIC ACID; AGGRECANASE 1; APOLIPOPROTEIN A1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD14 ANTIGEN; CD16 ANTIGEN; CD36 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISINTEGRIN; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRATE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GENETIC DIFFERENCE; HUMAN; HYPERCHOLESTEROLEMIA; MACROPHAGE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; RISK ASSESSMENT;

ANTIGENS, CD14; ANTIGENS, CD36; ATP BINDING CASSETTE TRANSPORTER 1; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MONOCYTES; RECEPTORS, IGG; SCAVENGER RECEPTORS, CLASS A;

EID: 84880332260     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32836236f9     Document Type: Review

References (63)

1. Gui T, Shimokado A, Sun Y, et al. Diverse Roles of Macrophages in Atherosclerosis:From Inflammatory Biology to Biomarker Discovery. Mediators Inflamm 2012; 2012:693083.
2. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145:341-355.
3. Berg KE, Ljungcrantz I, Andersson L, et al. Elevated CD14++. Circ Cardiovasc Genet 2012; 5:122-131.
4. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473:317-325.
5. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-212.
6. Hansson GK, Libby P. The immune response in atherosclerosis:A doubleedged sword. Nat Rev Immunol 2006; 6:508-519.
7. Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 2008; 18:228-232.
8. Kamei M, Carman CV. New observations on the trafficking and diapedesis of monocytes. Curr Opin Hematol 2010; 17:43-52.
9. Nakayama M, Kudoh T, Kaikita K, et al. Class A macrophage scavenger receptor gene expression levels in peripheral blood mononuclear cells specifically increase in patients with acute coronary syndrome. Atherosclerosis 2008; 198:426-433.
10. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013; 339:161-166.
11. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes:their role in infection and inflammation. J Leukoc Biol 2007; 81:584-592.
12. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116:e74-e80.
13. Hilgendorf I, Swirski FK. Making a difference:monocyte heterogeneity in cardiovascular disease. Curr Atheroscler Rep 2012; 14:450-459.
14. Gratchev A, Sobenin I, Orekhov A, et al. Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiology 2012; 217:476-482.
15. Rogacev KS, Cremers B, Zawada AM, et al. CD14++CD16+ monocytes independently predict cardiovascular events:A cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60:1512-1520.
16. Kashiwagi M, Imanishi T, Tsujioka H, et al. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis 2010; 212:171-176.
17. Mosig S, Rennert K, Krause S, et al. Different functions of monocyte subsets in familial hypercholesterolemia:potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. FASEB J 2009; 23:866-874.
18. Zeller T, Wild P, Szymczak S, et al. Genetics and beyond-The transcriptome of human monocytes and disease susceptibility. PLoS One 2010; 5:e10693.
19. Sivapalaratnam S, Basart H, Watkins NA, et al. Monocyte gene expression signature of patients with early onset coronary artery disease. PLoS One 2012; 7:e32166.
20. Davare MA, Avdonin V, Hall DD, et al. A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2. Science 2001; 293:98-101.
21. Catterall WA, Perez-Reyes E, Snutch TP, et al. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005; 57:411-425.
22. Iwamoto Y, Ohishi M, Yuan M, et al. beta-Adrenergic receptor gene polymorphism is a genetic risk factor for cardiovascular disease:A cohort study with hypertensive patients. Hypertens Res 2011; 34:573-577.
23. O'Byrne MR, Au KS, Morrison AC, et al. Association of folate receptor (FOLR1, FOLR2, FOLR3) and reduced folate carrier (SLC19A1) genes with meningomyelocele. Birth Defects Res A Clin Mol Teratol 2010; 88:689-694.
24. Yuan Y, Nymoen DA, Dong HP, et al. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol 2009; 40:1453-1460.
25. Antohe F, Radulescu L, Puchianu E, et al. Increased uptake of folate conjugates by activated macrophages in experimental hyperlipemia. Cell Tissue Res 2005; 320:277-285.
26. Sorrenson B, Suetani RJ, Williams MJ, et al. Functional rescue of mutant ABCA1 proteins by sodium 4-phenylbutyrate. J Lipid Res 2013; 54:55-62.
27. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis 2010; 211:361-370.
28. Brunham LR, Kastelein JJ, Hayden MR. ABCA1 gene mutations, HDL cholesterol levels, and risk of ischemic heart disease. JAMA 2008; 300:1997-1998.
29. Kanter JE, Tang C, Oram JF, et al. Acyl-CoA synthetase 1 is required for oleate and linoleate mediated inhibition of cholesterol efflux through ATP-binding cassette transporter A1 in macrophages. Biochim Biophys Acta 2012; 1821:358-364.
30. Bochem AE, van Wijk DF, Holleboom AG, et al. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. Eur Heart J 2013; 34:286-291.
31. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-offunction mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008; 299:2524-2532.
32. Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis 2010; 208:305-316.
33. Oram JF, Vaughan AM. ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006; 99:1031-1043.
34. Patino WD, Mian OY, Kang JG, et al. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci U S A 2005; 102:3423-3428.
35. Shen J, Chandrasekharan UM, Ashraf MZ, et al. Lack of mitogen-activated protein kinase phosphatase-1 protects ApoE-null mice against atherosclerosis. Circ Res 2010; 106:902-910.
36. Hagg S, Alserius T, Noori P, et al. Blood levels of dual-specificity phosphatase-1 independently predict risk for postoperative morbidities causing prolonged hospitalization after coronary artery bypass grafting. Int J Mol Med 2011; 27:851-857.
37. Kang JG, Sung HJ, Jawed SI, et al. FOS expression in blood as a LDLindependent marker of statin treatment. Atherosclerosis 2010; 212:567-570.
38. Wu C, Gong Y, Yuan J, et al. microRNA-181a represses ox-LDL-stimulated inflammatory response in dendritic cell by targeting c-Fos. J Lipid Res 2012; 53:2355-2363.
39. Saliques S, Teyssier JR, Vergely C, et al. Smoking and FOS expression from blood leukocyte transcripts in patients with coronary artery disease. Atherosclerosis 2011; 219:931-936.
40. Teupser D, Mueller MA, Koglin J, et al. CD36 mRNA expression is increased in CD14+ monocytes of patients with coronary heart disease. Clin Exp Pharmacol Physiol 2008; 35:552-556.
41. Piechota M, Banaszewska A, Dudziak J, et al. Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes. Protein J 2012; 31:511-518.
42. Sun B, Boyanovsky BB, Connelly MA, et al. Distinct mechanisms for OxLDL uptake and cellular trafficking by class B scavenger receptors CD36 and SRBI. J Lipid Res 2007; 48:2560-2570.
43. Kuchibhotla S, Vanegas D, Kennedy DJ, et al. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc Res 2008; 78:185-196.
44. Rac ME, Safranow K, Rac M, et al. CD36 gene is associated with thickness of atheromatous plaque and ankle-brachial index in patients with early coronary artery disease. Kardiol Pol 2012; 70:918-923.
45. Mosig S, Rennert K, Buttner P, et al. Monocytes of patients with familial hypercholesterolemia show alterations in cholesterol metabolism. BMC Med Genomics 2008; 1:60.
46. Methe H, Kim JO, Kofler S, et al. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111:2654-2661.
47. Marketou ME, Kontaraki JE, Zacharis EA, et al. TLR2 and TLR4 gene expression in peripheral monocytes in nondiabetic hypertensive patients:the effect of intensive blood pressure-lowering. J Clin Hypertens (Greenwich) 2012; 14:330-335.
48. den Dekker WK, Cheng C, Pasterkamp G, et al. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010; 209:314-320.
49. Franzeck FC, Hof D, Spescha RD, et al. Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. Atherosclerosis 2012; 220:282-286.
50. Devasagayam TP, Tilak JC, Boloor KK, et al. Free radicals and antioxidants in human health:current status and future prospects. J Assoc Physicians India 2004; 52:794-804.
51. De RS, Cirillo P, Paglia A, et al. Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease:does the actual knowledge justify a clinical approach? Curr Vasc Pharmacol 2010; 8:259-275.
52. Rocha M, Apostolova N, Hernandez-Mijares A, et al. Oxidative stress and endothelial dysfunction in cardiovascular disease:mitochondria-targeted therapeutics. Curr Med Chem 2010; 17:3827-3841.
53. Spychalowicz A, Wilk G, Sliwa T, et al. Novel therapeutic approaches in limiting oxidative stress and inflammation. Curr Pharm Biotechnol 2012; 13:2456-2466.
54. Yang HL, Xu YY, DU LF, et al. Chemokine SR-PSOX/CXCL16 expression in peripheral blood of patients with acute coronary syndrome. Chin Med J (Engl) 2008; 121:112-117.
55. Zha Y, Chen Y, Xu F, et al. Elevated level of ADAMTS4 in plasma and peripheral monocytes from patients with acute coronary syndrome. Clin Res Cardiol 2010; 99:781-786.
56. Wagsater D, Bjork H, Zhu C, et al. ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 2008; 196:514-522.
57. Chen SM, Li YG, Wang DM, et al. Expression of heme oxygenase-1, hypoxia inducible factor-1alpha, and ubiquitin in peripheral inflammatory cells from patients with coronary heart disease. Clin Chem Lab Med 2009; 47:327-333.
58. Leonard DA, Merhige ME, Williams BA, et al. Elevated expression of the interleukin-8 receptors CXCR1 and CXCR2 in peripheral blood cells in obstructive coronary artery disease. Coron Artery Dis 2011; 22:491-496.
59. Rosenson RS, Wright RS, Farkouh M, et al. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J 2012; 164:672-680.
60. Tontonoz P, Nagy L, Alvarez JG, et al.PPARgammapromotesmonocyte/ macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241-252.
61. Pucci A, Formato L, Muscio M, et al. PPARgamma in coronary atherosclerosis:in vivo expression pattern and correlations with hyperlipidemic status and statin treatment. Atherosclerosis 2011; 218:479-485.
62. Sueyoshi S, Mitsumata M, Kusumi Y, et al. Increased expression of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma in human atherosclerosis. Pathol Res Pract 2010; 206:429-438.
63. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.